Purchase Order 75N95019P00540
Award Date 9/6/19
Potential Completion Date 9/5/20
Potential Value $139K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Paramus, NJ 07652, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $122,400.00 firm fixed-price purchase order contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to Applied Stemcell, Inc., a minority-owned, woman-owned small business. The contract is for molecular and pathophysiological studies of Parkinson's disease dementia and does not have a set-aside designation. Applied Stemcell, Inc. provides gene editing services and good manufacturing practice (GMP) induced...
- This purchase order awards Fujifilm Cellular Dynamics, Inc. $349,700 for induced pluripotent stem (iPS) cell-derived differentiated cells to support the National Center for Advancing Translational Sciences within the National Institutes of Health's National Institute on Drug Abuse. The contract delivers over 300 units of various iPS cell-derived differentiated cells to develop three-dimensional tissue models of the brain. A pre-solicitation notice sought capability statements for a potential...
- This contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to Applied Stemcell, Inc., a minority-owned, woman-owned small business, for a firm-fixed-price purchase order in the amount of $63,000.00. The contract calls for the use of CRISPR gene editing technology to create two custom induced pluripotent stem cell (iPSC) reporter cell lines - one with dual gene knock-ins for albumin and alpha-fetoprotein, and...
- This is a $24,061 firm-fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the Department of Health and Human Services, to the foreign-owned, for-profit manufacturer Fujifilm Cellular Dynamics, Inc. The contract is for the supply of various induced pluripotent stem cell (iPSC)-derived human cell products, including cardiomyocytes, neurons, astrocytes, hepatocytes, and endothelial cells. These specialized cell lines are used in biomedical...
- This is a $24,900 firm-fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Center for Advancing Translational Sciences to 3Dnamics Inc., a biotechnology company that provides stem cell engineering technology and related services. The contract is for the differentiation of induced pluripotent stem cells (iPSCs) into hepatocyte organoids, which are three-dimensional cell cultures that model liver tissue. This work supports...
- The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences (NCATS) awarded a $150,000.00 firm fixed-price purchase order to 3Dnamics Inc., a biotechnology company, for services related to the differentiation and characterization of induced pluripotent stem cell (iPSC) lines. This non-competitive commercial item acquisition was conducted under simplified acquisition procedures without a small business set-aside. The services...
- The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $150,000.00 firm fixed-price purchase order contract to the New York Stem Cell Foundation Inc., a non-profit organization that conducts stem cell research. The contract is for services related to stem cell research, including generating induced pluripotent stem cell lines, differentiating stem cells into insulin-producing beta cells, and expanding and validating neural...
- This is a $241,500 firm fixed price contract awarded by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services, to the New York Stem Cell Foundation Inc., a non-profit organization. The contract is for the generation and characterization of human induced pluripotent stem cells (iPSCs), neural progenitor cells (NPCs), and stable transgenic iPSC lines from individuals with mood and anxiety disorders. This contract does not have a set-aside...
- The National Institute on Drug Abuse (NIDA) awarded a $164,226.56 firm-fixed-price purchase order to Infinity Biologix LLC on September 18, 2020, for induced pluripotent stem cell (iPSC) lines for derivation study. The contract was executed as a pre-solicitation opportunity that closed on July 29, 2019, with performance to be completed by January 31, 2022. Work is to be performed in Piscataway, New Jersey, where Infinity Biologix maintains its primary operations. This purchase order was issued...
- This is a $249,750.00 firm fixed-price definitive contract awarded by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse to the New York Stem Cell Foundation Inc., a non-profit organization. The contract is for services related to stem cell research, including generating induced pluripotent stem cell lines, differentiating stem cells, and expanding and validating neural progenitor cells from patients with conditions such as Alzheimer's...
This is a firm-fixed price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to PGI Holding Corporation, a for-profit subchapter S corporation. The contract, valued at $139,400.00, is for the engraftment of human induced pluripotent stem cell (iPSC) derived astrocytes into the forebrain of adult and neonatal wild type mice. The contract was awarded on a non-competitive basis under simplified acquisition procedures and has no set-aside designation. The source of the requirement is the NIH's National Center for Advancing Translational Sciences (NCATS), and the period of performance is 24 weeks.
Generated 3/23/24, 1:44 AM
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
Engraftment of human iPSC derived astrocytes into the forebrain of adult and neonatal wild type mice | 75N95019Q00277 | Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse | Solicitation 1/1 | 8/1/19, 8:57 AM |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $139.4k | 9/6/19 |